Comparison of the Treatment Results for Behçet Uveitis in Patients Treated with Infliximab and Interferon

References

• Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M. Uveitis in Behçet disease: an analysis of 880 patients. Am J Ophthalmol. 2004;138:373–380. doi:10.1016/j.ajo.2004.03.022.
   PubMed Web of Science ®Google Scholar
• Takeuchi M, Hokama H, Tsukahara R, et al. Risk and prognostic factors of poor visual outcome in Behçet’s disease with ocular involvement. Graefe’s Arch Clin Exp Ophthalmol. 2005;243:1147–1152. doi:10.1007/s00417-005-0005-8.
   PubMed Web of Science ®Google Scholar
• Okada AA, Goto H, Ohno S, Mochizuki M. Multicenter study of infliximab for refractory uveoretinitis in Behçet disease. Arch Ophthalmol. 2012;130:592–598. doi:10.1001/archophthalmol.2011.2698.
   PubMed Web of Science ®Google Scholar
• Takeuchi M, Kezuka T, Sugita S, et al. Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet’s disease: a multicenter study. Ophthalmology. 2014;121:1877–1884. doi:10.1016/j.ophtha.2014.04.042.
   PubMed Web of Science ®Google Scholar
• Vallet H, Riviere S, Sanna A, et al. Efficacy of anti-TNF alpha in severe and/or refractory Behçet’s disease: multicenter study of 124 patients. J Autoimmun. 2015;62:67–74. doi:10.1016/j.jaut.2015.06.005.
   PubMed Web of Science ®Google Scholar
• Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;121(786–96):e3. doi:10.1016/j.ophtha.2013.09.048.
   Google Scholar
• Keino H, Okada AA, Watanabe T, Taki W. Long-term efficacy of infliximab on background vascular leakage in patients with Behçet’s disease. Eye. 2014;28(9):1100–1106. doi:10.1038/eye.2014.138.
   PubMed Web of Science ®Google Scholar
• Kötter I, Eckstein AK, Stübiger N, et al. Treatment of ocular symptoms of Behçet’s disease with interferon α2a: a pilot study. British J Ophthalmol. 1998;82:488–494.
   PubMed Web of Science ®Google Scholar
• Deuter CME, Zierhut M, Möhle A, Vonthein R, Stöbiger N, Kötter I. Long-term remission after cessation of interferon-α treatment in patients with severe uveitis due to Behçet’s disease. Arthritis Rheumatism. 2010;62(9):2796–2805.10. doi:10.1002/art.27581.
   PubMed Web of Science ®Google Scholar
• Sobaci G, Erdem U, Durukan AH, et al. Safety and effectiveness of interferon alpha-2a in treatment of patients with Behcet’s uveitis refractory to conventional treatments. Ophthalmology. 2010;117(7):1430–1435.11. doi:10.1016/j.ophtha.2009.11.022.
   PubMed Web of Science ®Google Scholar
• Onal S, Kazokoglu H, Koc A, et al. Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behcet uveitis. Arch Ophthalmol. 2011;129(3):288–294. doi:10.1001/archophthalmol.2011.3.
   PubMed Web of Science ®Google Scholar
• International Team for the Revision of the International Criteria for Behcet’s Disease. Revision of the International Criteria for Behcet’s Disease (ICBD). Clin Exp Rheumatol. 2006;24(Suppl 42): S14– S15.
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology. 1985;92(4):467–471. doi:10.1016/S0161-6420(85)34001-0.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT, et al. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140:509–516. doi:10.1016/j.ajo.2005.03.057.
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Herbort CP, Khairallah M, et al. Scoring of dual fluorescein and ICG inflammatory angiographic signs for the grading of posterior segment inflammation (dual fluorescein and ICG angiographic scoring system for uveitis). Int Ophthalmol. 2010;30:539. doi:10.1007/s10792-008-9263-x.
   PubMedGoogle Scholar
• Ozguler Y, Leccese P, Christiensen R, et al. Management of major organ involvement of Behçet’s syndrome: a systematic review for update of the EULAR recommendations. Rheumatology. 2018;57(12):2200–2212.
   Web of Science ®Google Scholar
• Kim M, Kwon HJ, Choi EY, Kim SS, Koh HJ, Lee SC. Correlation between fluorescein angiographic findings and visual acuity in Behçet retinal vasculitis. Yonsei Med J. 2015;56(4):1087–1096. doi:10.3349/ymj.2015.56.4.1087.
   PubMed Web of Science ®Google Scholar
• Ladas JG, Wheeler NC, Morhun PJ, Rimmer SO, Holland GN. Laser flare-cell photometry; methodology and clinical applications. Surv Ophthalmol. 2005;50:27–47. doi:10.1016/j.survophthal.2004.10.004.
   PubMed Web of Science ®Google Scholar
• Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behçet‘s syndrome. Ann Rheum Dis. 2018 Jun;77(6):808–818. doi:10.1136/annrheumdis-2018-213225.
   PubMed Web of Science ®Google Scholar
• Mage JL, Dilsen N, Sanguedolce V, et al. Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behçet’s disease: a comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol. 1993;20:1544–1549.
   PubMed Web of Science ®Google Scholar
• Evereklioglu C, Er H, Turkoz Y, Cekmen M. Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behcet’s disease. Mediators Inflamm. 2002;11(2):87–93. doi:10.1080/09629350220131935.
   PubMed Web of Science ®Google Scholar
• Santos Lacomba M, Marcos Martin C, Gallardo Galera JM, et al. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res. 2001;33(5):251–255. doi:10.1159/000055677.
   PubMed Web of Science ®Google Scholar
• Misumi M, Hagiwara E, Takeno M, et al. Cytokine production profile in patients with Behçet’s disease treated with infliximab. Cytokine. 2003;24:210–218. doi:10.1016/j.cyto.2003.09.003.
   PubMed Web of Science ®Google Scholar
• Turan B, Gallati H, Erdi H, et al. Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Bechçet‘s disease; soluble TNFR-75 as a biological marker of disease activity. J Rheumatol. 1997;24(1):128–132.
   PubMed Web of Science ®Google Scholar
• Nanke Y, Kotake S, Goto M, Ujihara H, Matsubara M, Kamatani N. Decreased percentages of regulatory T cells in peripheral blood of patients with Behcet‘s diseasebefore ocular attack: a possible predictive marker of ocular attack. Mod Rheumatol. 2008;18(4):354–358. doi:10.1007/s10165-008-0064-x.
   PubMed Web of Science ®Google Scholar
• Ozdal PC, Ortac¸ S, Taskintuna I, Firat E. Posterior segment involvement in ocular Behcet’s disease. Eur J Ophthalmol. 2002;12:424–431.32. doi:10.1177/112067210201200514.
   PubMed Web of Science ®Google Scholar
• Markomichelakis NN, Theodossiadis PG, Pantelia E, et al. Infliximab for chronic cycstoid macular edema associated with uveitis. Am J Ophthalmol. 2004;138:648–650. doi:10.1016/j.ajo.2004.04.066.
   PubMed Web of Science ®Google Scholar
• Lejoyeux R, Diwo E, Vallet H, et al. Infliximab and Adalimumab in uveitic macular edema. Ocul Immunol Inflamm. Aug 2018;10:1–6.
   Google Scholar
• Nussenblatt RB, Thompson DJ, Li Z, et al. Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J Autoimmun. 2003;21(3):283–293.
   PubMed Web of Science ®Google Scholar
• Baneros-Rojas P, Berrozpe-Villabona C, Peraza-Nieves JE, DiazValle D. Early treatment with infliximab in bilateral occlusive vasculitis as a presenting manifestation of Behçet’ disease. Arch Soc Esp Oftalmol. 2015;90:285–288.
   PubMedGoogle Scholar
• Ito T, Sonoda KH, Hijioka K, Fujimoto T, Ishibashi T. Acquired resistance to infliximab against uveitis due to Behçet’s disease after one year of administration. Jpn J Ophthalmol. 2010;54:502–504. doi:10.1007/s10384-010-0859-0[21].
   PubMed Web of Science ®Google Scholar
• Suhler EB, Smith JR, Wertheim MS. et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol. 2005;123:903–912. doi:10.1001/archopht.123.7.903.
   PubMed Web of Science ®Google Scholar
• Sfikakis PP, Markomichelakis N, Alpsoy E, et al. Anti-TNF therapy in the management of Behçet‘s disease—review and basis for reccomendations. Rheumatology. 2007:736–741. doi:10.1093/rheumatology/kem034.
   PubMedGoogle Scholar
• Krause L, Altenburg A, Pleyer U, et al. Longterm visual prognosis of patients with ocular Adamantiades-Behçet’s disease treated with interferon-alpha-2a. J Rheumatol. 2008;35(5):896–903.
   PubMed Web of Science ®Google Scholar
• Zierhut M, Abu El-Asrar AM, Bodaghi B, Tugal-Tutkun I. Therapy of ocular Behçet disease. Ocul Immunol Inflamm. 2014;22:64–76. doi:10.3109/09273948.2013.866257.
   PubMed Web of Science ®Google Scholar
• Deuter CME, Kötter I, Günaydin I, et al. Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis. British J Ophthalmol. 2009;93:906–913. doi:10.1136/bjo.2008.153874.
   PubMed Web of Science ®Google Scholar
• Belardelli F, Gresser I. The neglected role of type I interferon in the T-cell response: implications for its clinical use. Immunol Today. 1996;17:369–372. doi:10.1016/0167-5699(96)10027-X.
   PubMedGoogle Scholar
• Yang DS, Talylor SR, Lightman SL. Interferon alpha in the management of patients with Behçet’s disease. Br J Hosp Med (Lond). 2008;69:575–579. doi:10.12968/hmed.2008.69.10.31317.
   PubMed Web of Science ®Google Scholar
• Tilg H, Mier JW, Vogel W, et al. Induction of circulating IL-1 receptor antagonist by IFN treatment. J Immunol. 1993;150(10):4687–4692.
   PubMed Web of Science ®Google Scholar
• Yeung IY, Popp NA, Chan CC, et al. The role of sex in uveitis and ocular inflammation. Int Ophthalmol Clin 2015 ;55(3):111–131. doi:10.1097/IIO.0000000000000072.
   PubMedGoogle Scholar
• Onal S, Kazokoglu H, Koc A, et al. Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behçet uveitis. Arch Ophthalmol. 2011 Mar;129(3):288–294. doi:10.1001/archophthalmol.2011.3.
   PubMed Web of Science ®Google Scholar
• Wechsler B, Bodaghi B, Huong DL, et al. Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behc¸et’s disease. Ocul Immunol Inflamm. 2000;8(4):293–301.
   PubMed Web of Science ®Google Scholar
• Gueudry J, Wechsler B, Terrada C, et al. Long-term efficacy and safety of lowdose interferon alpha2a therapy in severe uveitis associated with Behc¸et disease. Am J Ophthalmol. 2008;146(6):837.e1-844.e1.doi:10.1016/j.ajo.2008.08.038.
   PubMed Web of Science ®Google Scholar
• Kötter I, Zierhut M, Eckstein AK, et al. Human recombinant interferon alfa-2a for the treatment of Behçet‘s disease with sight threatening posterior or panuveitis. British J Ophthalmol. 2003;87:423–431.
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Güney-Tefekli E, Urgancioglu M. Results of interferon-alfa therapy in patients with Behçet uveitis. Graefes Arch Clin Exp Ophthalmol. 2006 Dec;244(12):1692–1695. doi:10.1007/s00417-006-0346-y.
   PubMed Web of Science ®Google Scholar
• Aydinoglu-Candan Ö, Araz-Erşan B, Gul A, Badur S, Tugal-Tutkun I. Anti-interferon alpha antibodies and autoantibodies in patients with Behçet’s disease uveitis treated with recombinant human interferon alpha-2a. Graefes Arch Clin Exp Ophthalmol. 2015 Mar;253(3):457–465. doi:10.1007/s00417-014-2856-3.
   PubMed Web of Science ®Google Scholar
• Alpsoy E, Yılmaz E, Basaran E. Interferon therapy for Behçet’s disease. J Am Acad Dermatol. 1994;31:617–619.
   PubMed Web of Science ®Google Scholar
• O’Duffy JD, Calamia K, Cohen S, et al. Interferon-α treatment of Behçet’s disease. J Rheumatol. 1998;25:1938–1944.
   PubMed Web of Science ®Google Scholar
• Georgiou S, Monastirli A, Pasmatzi E, Gartaganis S, Goerz G, Tsambaos D. Efficacy and safety of systemic recombinant interferon-alpha in Behçet’s disease. J Intern Med. 1998;243:367–372.
   PubMed Web of Science ®Google Scholar
• Niccoli L, Nannini C, Benucci M, et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet’s disease: a 24-month follow-up study. Rheumatology (Oxford). 2007;46:1161–1164. doi:10.1093/rheumatology/kem045.
   PubMed Web of Science ®Google Scholar
• Kaçmaz RO, Kempen JH, Newcomb C, et al. Ocular inflammation in Behçet disease: incidence of ocular complications and of loss of visual acuity. Am J Ophthalmol. 2008;146(6):828–836. doi:10.1016/j.ajo.2008.06.019.
   PubMed Web of Science ®Google Scholar
• Hamuryudan V, Ozyazgan Y, Fresko Y, Mat C, Yurdakul S, Yazici H. Interferon alfa combined with azathioprine for the uveitis of Behcet’s disease: an open study. IMAJ. 2002 Nov;4(11 Suppl):928–930.
   Google Scholar
• Evereklioglu C. Current concepts in the etiology and treatment of Behcet disease. Surv Ophthalmol. 2005;50(4):297–350. doi:10.1016/j.survophthal.2005.04.009.
   PubMed Web of Science ®Google Scholar
• Alabdulaaly A, Rifkind J, Solow H, Messner HA, Lipton JH. Rescue of interferon induced bone marrow aplasia in a patient with chronic myeloid leukemia by allogeneic bone marrow transplant. Leuk Lymphoma. 2004;45(1):175–177. doi:10.1080/1042819031000139774.
   PubMed Web of Science ®Google Scholar
• Bodaghi B, Gendron G, Wechsler B, et al. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol. 2007;91(3):335–339. doi:10.1136/bjo.2006.101550.
   PubMed Web of Science ®Google Scholar
• Pay S, Simsek I, Erdem H, et al. Immunopathogenesis of Behcet’s disease with special emphasize on the possible role of antigen presenting cells. Rheumatol Int. 2007;27(5):417–424. doi:10.1007/s00296-006-0281-6.
   PubMed Web of Science ®Google Scholar